SCHEMBL2226466

SCHEMBL2226466

OCc1cc2ccc(Br)cc2cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.44
CYP2A6 P11509 1/20 0.42
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
CCR1 P32246 1/20 0.36
GSK3A P49840 1/20 0.36
CDK9 P50750 1/20 0.36
CDK5 Q00535 1/20 0.36
TAOK1 Q7L7X3 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
NOS1 P29475 2/20 0.35
METAP2 P50579 2/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30718639 1.00 ABL1 (0.44) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL1641540 0.86 ABL1 (0.42) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL10272932 0.81 CYP2A6 (0.42) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL3636138 0.78 S1PR4 (0.43) ABL1CYP2A6ALDH1A1KDM4EMAPT
SCHEMBL2226121 0.77 ABL1 (0.41) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL1999306 0.76 ATM (0.51) CYP2A6ALDH1A1CCR1CYP1A2L3MBTL1
SCHEMBL19792367 0.76 CYP2A6 (0.46) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL23706012 0.76 GSK3A (0.43) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL30042006 0.76 GSK3A (0.43) ABL1CYP2A6ALDH1A1KDM4EMEN1
SCHEMBL2749215 0.75 ABL1 (0.47) ABL1CYP2A6ALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547658-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF Bristol-Myers Squibb Company (US) 2025-05-07 EP disclosed
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2024-02-29 US disclosed
WO-2024006881-A1 WEE1 DEGRADING COMPOUNDS AND USES THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2024-01-04 WO disclosed
WO-2011091446-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-07-28 WO disclosed
WO-2011091446-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067632-A1 WEE1 Degrading Compounds and Uses Thereof WEE1, WEE2, PPME1 ABL1 1361/4885CYP2A6 3665/4885ALDH1A1 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.